Cuban Monoclonal Antibodies Plant Opens in China
Nancy Zamora
Beijing, Sep 26 (Prensa Latina) A plant to produce humanized monoclonal antibodies developed by Cuban scientists, to treat neck and head cancer opened Monday in Beijing.
The Chinese-Cuban Biotech Pharmaceutical Company will produce and commercialize hR-3 antibody, obtained by scientists of Cuba's Center of Molecular Immunology (CIM).
The hR-3 has Cuban and Chinese medical registry plus patents given in Canada, the US, China and various European countries.
The modern plant was opened on the occasion of 45th anniversary of Cuba- China relations, established in September 28, 1960.
The opening ceremony was chaired by Cuba's Government Minister Ricardo Cabrisas and vice Minister of National Development and Reform Commission Zhang Xiaoqiang, plus CIM director Agustin Lage and Cuban ambassador in China Alberto Rodriguez Arufe.
Cabrisas recalled the island was the first country in the Americas to have links with Popular Republic of China.
Agustin Lage said the plant was of a new type with complex manufacture processes, intense scientific activity and a high-qualified work force.
Patricia Sierra, in charge of Cuban part of the project, told Prensa Latina the plant would add clinical trials and the production of other antibodies and vaccines developed in CIM.
It also sets scientific and technological bases for Cuban-Chinese joint investigations in medicines to treat different kinds of cancers.
The TheraCIM h-R3 is the first humanized monoclonal antibody approved in Cuba for treatment of neck and head cancer, also the third in the world, and will be the first one to be produced in China.
Last Saturday, another plant for the production, registry and commercialization of vaccines and recombinant therapeutic proteins, with Cuban technology, was inaugurated in the northeastern Chinese province of Jilin.
plenglish.com |
